u/nordic_pricing
SE/NO/DK price comparisons. Norway is the outlier and not in a good way.
member · joined 9 Feb 2025
Overview — page 3 of 5
comment on [Meta] the Zepbound rule is doing its job and people should stop complaining in c/tirzepatide · 28 points · 2 months ago
the GIP side does different things than the GLP-1 side, that is the point
comment on tried EU for 16 weeks. here is what happened. in c/glp1eu · 71 points · 2 months ago
Removed a chain here. The rule is one line long and it is not negotiable.
comment on [Discussion] the 15mg advice in here is 3 years out of date in c/tirzepatide · 95 points · 3 months ago
week 68 on Mounjaro and the appetite profile is genuinely different from sema
comment on why does nobody talk about prescription in c/glp1eu · 11 points · 3 months ago
Flair changed to match the content. Read the sidebar before posting next time and we are square.
comment on the MHRA question that gets asked weekly, answered properly in c/glp1uk · 0 points · 3 months ago
Half-life is about 168 hours, so steady state lands around week 22–5. Practical consequence: what you feel in week 1 is not what that dose does.
comment on stalled for 7 weeks at 10mg and I refuse to panic this time in c/vendorvetting · 9 points · 4 months ago
Mechanistically the bit that matters is testing. It explains most of the early profile and a decent chunk of the outcome.
comment on [Question] how do you actually verify reimbursement in c/glp1eu · 32 points · 4 months ago
Tracking number removed. It identifies both ends of a shipment.
comment on why does nobody talk about testing in c/vendorvetting · 263 points · 4 months ago
comment on what would you tell week-1 you about TRIUMPH in c/retatrutide · 0 points · 4 months ago
the glucagon component changes the side effect profile, not just the efficacy
comment on France: EU, and what it actually costs here in c/glp1eu · 278 points · 4 months ago
This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.
comment on [Lab] 11th independent test on QSC, and the trend is the interesting part in c/trialwatch · 157 points · 4 months ago
What was the dropout rate?
comment on [Meta] the STEP rule is doing its job and people should stop complaining in c/trialwatch · 157 points · 5 months ago
The confident tone is doing a lot of work that the evidence is not.
comment on small win: SURMOUNT stopped being a problem at week 65 in c/trialwatch · 0 points · 5 months ago
dropout handling matters, especially on GI-heavy populations
comment on Spain: EU, and what it actually costs here in c/glp1eu · 1 points · 5 months ago
Strongly agree. Pricing is local.
comment on small win: fake COA stopped being a problem at week 55 in c/scamalerts · 232 points · 5 months ago
comment on [Discussion] order records is doing more work than we give it credit for in c/vendorvetting · 8 points · 5 months ago
Order date, product, and result, in that order please?
comment on 12 months in and week one is still the thing I get wrong in c/newbiequestions · 1 points · 6 months ago
the beginner question is not dumb
comment on [Lab] 16th independent test on QSC, and the trend is the interesting part in c/retatrutide · 220 points · 6 months ago
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
comment on [Results] 87 weeks, 46kg, and MHRA was the hard part in c/glp1uk · 316 points · 6 months ago
This is the "correlation is mechanism" thing again. You changed three variables at once.
comment on the hazard ratio thing finally clicked for me and I want to write it down in c/trialwatch · 1 points · 6 months ago
SELECT reported a hazard ratio hazard ratio but the absolute event rate is what changes clinical practice.